- Home
- SBRA vs VKTX Comparison
SBRA vs VKTX Comparison
Compare SBRA & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBRA | VKTX |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.4B |
| IPO Year | 2010 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SBRA | VKTX |
|---|---|---|
| Price | $20.39 | $33.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $22.00 | ★ $95.86 |
| AVG Volume (30 Days) | ★ 2.4M | 1.9M |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | ★ 5.90% | N/A |
| EPS Growth | ★ 18.52 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $774,632,000.00 | N/A |
| Revenue This Year | $7.50 | N/A |
| Revenue Next Year | $9.07 | N/A |
| P/E Ratio | $342.17 | ★ N/A |
| Revenue Growth | ★ 10.15 | N/A |
| 52 Week Low | $17.17 | $22.96 |
| 52 Week High | $22.81 | $43.15 |
Technical Indicators
Market Signals| Indicator | SBRA | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.78 | 47.04 |
| Support Level | $19.54 | $32.24 |
| Resistance Level | $20.80 | $35.24 |
| Average True Range (ATR) | 0.47 | 1.27 |
| MACD | -0.08 | 0.13 |
| Stochastic Oscillator | 37.77 | 33.76 |
Price Performance
Historical ComparisonAbout SBRA Sabra Health Care REIT Inc.
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.